← FDA DRUG APPROVALS

FDA ANDA · ANDA210531

DIMETHYL FUMARATE

Sponsor: MYLAN

APPLICATION
ANDA210531
TYPE
ANDA
ORIGINAL APPROVAL
2020-08-17
LATEST ACTION
2024-04-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

DIMETHYL FUMARATEDiscontinued
DIMETHYL FUMARATE 120MG · CAPSULE, DELAYED RELEASE · ORAL
DIMETHYL FUMARATEDiscontinued
DIMETHYL FUMARATE 240MG · CAPSULE, DELAYED RELEASE · ORAL

Approval history

2024-04-30Labeling · Supplement 6 · standardAP
2024-04-30Labeling · Supplement 12 · standardAP
2024-04-30Labeling · Supplement 10 · standardAP
2024-04-30Labeling · Supplement 3 · standardAP
2024-04-30Labeling · Supplement 13 · standardAP
2021-06-17Manufacturing (CMC) · Supplement 1 · unknownAP
2020-08-17UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →